News
ASCO 25: AZ pitches upfront oral SERD use in breast cancer
AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.
Monday 9 June 2025
